EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A

Lynn Malec, Flora Peyvandi iD, Anthony K C Chan, Christoph Königs, Bulent Zulfikar, Huixing Yuan, Mindy Simpson, Maria Teresa Álvarez Román, Manuel Carcao, Janice M Staber, Amy L Dunn, Sheng-Chieh Chou und 10 weitere

New England Journal of Medicine · 18.07.2024 · 391 (3) · 235-246

DOI: 10.1056/nejmoa2312611 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.07.2024. Verfasst von Lynn Malec und 21 weiteren Autor:innen. Beteiligte Einrichtung: From Versiti Blood Research Institute, and the Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wiscon…. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Hemorrhage, Recombinant Proteins. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Sanofi, Sobi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AHemorrhageRecombinant ProteinsChildChild, PreschoolHumansInfantMaleAntibodies, NeutralizingDrug Administration ScheduleJoint DiseasesQuality of Life

Substanzen

Antibodies, NeutralizingFactor VIIIRecombinant Proteins

Autor:innen und Institutionen

  • From Versiti Blood Research Institute, and the Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin - both in Milwaukee (L.M.); IRCCS Ca' Granda Maggiore Hospital Fou…

ORCID-Profile: Flora Peyvandi

Förderung

  • Sanofi
  • Sobi

Zitieren

APA

Malec, L., Peyvandi, F., Chan, A. K. C., Königs, C., Zulfikar, B., Yuan, H., Simpson, M., Álvarez Román, M. T., Carcao, M., Staber, J. M., Dunn, A. L., Chou, S. C., d'Oiron, R., Albisetti, M., Demissie, M., Santagostino, E., Yarramaneni, A., Wong, N., Abad-Franch, L., …, & XTEND-Kids Trial Group (2024). Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A. New England Journal of Medicine, 391(3), 235-246. https://doi.org/10.1056/nejmoa2312611

Vancouver

Malec L, Peyvandi F, Chan AKC, Königs C, Zulfikar B, Yuan H, et al. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A. New England Journal of Medicine. 2024;391(3):235-246. doi:10.1056/nejmoa2312611

BibTeX
@article{Malec2024,
  author = {Malec, Lynn and Peyvandi, Flora and Chan, Anthony K C and Königs, Christoph and Zulfikar, Bulent and Yuan, Huixing and Simpson, Mindy and Álvarez Román, Maria Teresa and Carcao, Manuel and Staber, Janice M and Dunn, Amy L and Chou, Sheng-Chieh and d'Oiron, Roseline and Albisetti, Manuela and Demissie, Marek and Santagostino, Elena and Yarramaneni, Abhimanyu and Wong, Nancy and Abad-Franch, Lydia and Gunawardena, Sriya and Fijnvandraat, Karin and XTEND-Kids Trial Group, XTEND-Kids Trial Group},
  title = {Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {3},
  pages = {235--246},
  doi = {10.1056/nejmoa2312611}
}
Kostenlos starten →